Affinity Investment Advisors LLC Sells 3,524 Shares of Horizon Pharma PLC (HZNP)

Affinity Investment Advisors LLC lowered its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 11.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,184 shares of the biopharmaceutical company’s stock after selling 3,524 shares during the period. Affinity Investment Advisors LLC’s holdings in Horizon Pharma were worth $551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. D.A. Davidson & CO. grew its stake in shares of Horizon Pharma by 5.1% in the 4th quarter. D.A. Davidson & CO. now owns 10,592 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 512 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Horizon Pharma by 10.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,271 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 1,149 shares in the last quarter. Private Capital Group LLC lifted its position in Horizon Pharma by 141.5% in the 4th quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,150 shares in the last quarter. United Services Automobile Association lifted its position in Horizon Pharma by 11.0% in the 2nd quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 2,679 shares in the last quarter. Finally, Globeflex Capital L P lifted its position in Horizon Pharma by 2.5% in the 3rd quarter. Globeflex Capital L P now owns 124,659 shares of the biopharmaceutical company’s stock valued at $2,441,000 after acquiring an additional 3,000 shares in the last quarter. Institutional investors own 90.32% of the company’s stock.

Several equities analysts recently issued reports on HZNP shares. Stifel Nicolaus upped their price objective on Horizon Pharma from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, November 1st. BidaskClub raised Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 5th. TheStreet raised Horizon Pharma from a “c” rating to a “b-” rating in a research report on Tuesday, November 20th. Mizuho reaffirmed a “buy” rating on shares of Horizon Pharma in a research report on Tuesday, October 16th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Horizon Pharma in a research report on Thursday, October 18th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.33.

NASDAQ HZNP opened at $23.04 on Tuesday. The firm has a market cap of $3.84 billion, a PE ratio of 19.53, a PEG ratio of 1.14 and a beta of 1.15. The company has a current ratio of 1.94, a quick ratio of 1.86 and a debt-to-equity ratio of 2.06. Horizon Pharma PLC has a 1-year low of $12.55 and a 1-year high of $24.03.

In other news, Chairman Timothy P. Walbert sold 408,347 shares of the stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the transaction, the chairman now directly owns 650,404 shares of the company’s stock, valued at approximately $14,009,702.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Geoffrey M. Curtis sold 8,835 shares of the stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the transaction, the executive vice president now directly owns 32,202 shares in the company, valued at $745,476.30. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2019/02/12/affinity-investment-advisors-llc-sells-3524-shares-of-horizon-pharma-plc-hznp.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Featured Story: Why is Cost of Capital Important?

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.